Cardiac computed tomography angiography-derived analysis of left atrial appendage morphology and left atrial dimensions for the prediction of atrial fibrillation recurrence after pulmonary vein isolation

Florian Straube M.D., FESC, FHRS¹,⁵ | Janis Pongratz M.D.¹ | Stefan Hartl M.D.¹ | Benedikt Brueck M.D.¹,⁷ | Christian Tesche M.D., MHBA, FESC⁴,⁵ | Ullrich Ebersberger M.D.¹,⁵,⁶ | Thomas Helmberger M.D.² | Alexander Crispin M.D., MPH³ | Michael Wankerl M.D.¹ | Uwe Dorwarth M.D.¹ | Ellen Hoffmann M.D., FESC¹

¹Heart Center Munich-Bogenhausen, Department of Cardiology and Internal Intensive Care Medicine, Munich Clinic Bogenhausen, Academic Teaching Hospital of the Technical University Munich, Munich, Germany
²Department of Radiology, Neuroradiology and Nuclear Medicine, Munich Clinic Bogenhausen, Academic Teaching Hospital of the Technical University Munich, Munich, Germany
³Institute for Medical Information Processing, Biometry and Epidemiology, Ludwig-Maximilians-University, Munich, Germany
⁴Department of Cardiology, St. Johannes Hospital Dortmund, Dortmund, Germany
⁵Faculty of Medicine and the University Hospital, Dept. of Cardiology, Ludwig-Maximilians-University, Munich, Germany
⁶KMN, Kardiologie Muenchen Nord, Munich, Germany
⁷Internal Medicine and Cardiology, Kardiologie Erkelenz, Erkelenz, Germany

Abstract

Background: Left atrial appendage (LAA) is a potential source of atrial fibrillation (AF) triggers.

Hypothesis: LAA morphology and dimensions are associated with AF recurrence after pulmonary vein isolation (PVI).

Methods: From cardiac computed tomography angiography (CCTA), left atrial (LA), pulmonary vein (PV), and LAA anatomy were assessed in cryoballoon ablation (CBA) patients.

Results: Among 1103 patients undergoing second-generation CBA, 725 (65.7%) received CCTA with 473 (42.9%) qualifying for detailed LAA analysis (66.3 ± 9.5 years). Symptomatic AF reoccurred in 166 (35.1%) patients during a median follow-up of 19 months. Independent predictors of recurrence were LA volume, female sex, and mitral regurgitation ≥ II. LAA volume and AF-type were dependent predictors of recurrence due to their strong correlations with LA volume. LA volumes ≥ 122.7 ml (sensitivity 0.53, specificity 0.69, area under the curve [AUC] 0.63) and LAA volumes ≥ 11.25 ml (sensitivity 0.39, specificity 0.79, AUC 0.59) were associated with recurrence. LA volume was significantly smaller in females. LAA volumes showed no sex-specific difference. LAA morphology, classified as windsock (51.4%), chicken-wing (20.7%), cactus (12.5%), and cauliflower-type (15.2%), did not predict successful PVI (log-rank; p = 0.596).

Conclusions: LAA volume was strongly correlated to LA volume and was a dependent predictor of recurrence after CBA. Main independent predictors were LA volume.
Funding information
A research agreement between the local institution and Abbott Medical exists, and the most recent clinical software of EnSite Precision™ (Abbott Medical GmbH, Eschborn, Germany) was provided for the CT reconstruction and post-processing of the CCTA images.

Female sex, and mitral regurgitation ≥II. Gender differences in LA volumes were observed. Individual LAA morphology was not associated with AF recurrence after cryo-PVI. Our results indicate that preprocedural CCTA might be a useful imaging modality to evaluate ablation strategies for patients with recurrences despite successful PVI.

KEYWORDS
atrial fibrillation, cryoballoon ablation, left atrial appendage, morphology, pulmonary vein isolation

1 | INTRODUCTION

Left atrial appendage (LAA) morphology can be determined by cardiac computed tomography angiography (CCTA). However, the role of the LAA in the initiation and perpetuation of AF has to be defined further. Pulmonary vein electrical isolation (PVI) is the standard strategy at the initial ablation procedure for the treatment of paroxysmal and persistent atrial fibrillation (AF). Despite continuing technical improvements, a significant proportion of patients have recurrence after the first ablation procedure. Several mechanisms causing recurrence have been identified. Electrical reconnection of the PVs is the main mechanism, and gap closure in the second procedure remains the standard of care. With the introduction of next generation ablation catheters and smart ablation protocols, the majority of PVs show durable isolation. Additional lesions beyond PV isolation (PVI) (e.g., empirical lines, complex fractionated electrograms, ganglionated plexi, triggers) have been studied, but until now, these measures have not demonstrated additional benefit as compared to PVI alone in the initial ablation procedure. Clinical predictors of AF recurrence after catheter ablation are LA size, AF type, female sex, and in-hospital AF relapse, as well as comorbidities such as impaired cardiac and renal function. LAA itself might also be a source of extra-PV AF triggers or might serve as the substrate of perpetuating AF, though it is unknown whether the LAA anatomy correlates with the recurrence rate after PVI. LAA is a complex anatomical structure with substantial variation in size and morphology; it is not possible to determine LAA morphology or LA size through transthoracic echocardiography (TTE). However, CCTA is the best modality to determine LAA morphology and atrial dimensions. Other benefits from preprocedural cardiac computed tomography angiography (CCTA) include ruling out possible thrombi, detecting underlying coronary artery disease (CAD), and gaining advanced information of individual PV anatomy.

The present study sought to investigate whether LAA morphology and detailed measurement of a variety of LAA and LA parameters, determined by CCTA, can predict atrial arrhythmia recurrence after initial cryoballoon PVI in symptomatic AF patients.

2 | METHODS

2.1 | Study design

This prospective single-centre registry study enrolled consecutive patients undergoing second-generation CBA between May 2012 and September 2016. Informed consent was obtained from all patients. The study was approved by the regional ethics review board and was conducted in accordance with the Declaration of Helsinki.

2.2 | Study participants

Consecutive symptomatic patients scheduled for the initial AF ablation procedure aiming at PV isolation were treated with the second-generation cryoballoon (Arctic Front Advance™, Medtronic Inc., MN, USA) and were prospectively enrolled into the institutional observational registry. If a recent preprocedural CCTA of sufficient quality to assess the LAA anatomy was available, the patient was considered for the present blinded analysis. The clinical indications for CCTA were, firstly, exclusion of CAD, and secondly, determination of LA and PV anatomy prior to the CBA. No patient was excluded from cryoballoon ablation based on variations in LA, PV, LAA anatomy, or LA volume, as determined by CCTA. None of the consecutive patients were treated by means of point-by-point radiofrequency (RF) ablation for PVI. Standard exclusion criteria for AF ablation were applied. Baseline characteristics were collected prospectively.

2.3 | Objectives and endpoints

The primary objective of the study was to evaluate the impact of LAA anatomy and morphology on the recurrence of AF after CBA. The secondary objective was the general determination of possible independent clinical risk factors for AF recurrence.

2.4 | Preprocedural investigations

Prior to the ablation procedure, all patients underwent transthoracic and transesophageal echocardiography to exclude possible LA
thrombus formation. Additionally, individual left atrial anatomy was revealed using a 64-slice CT scanner (Brilliance 64, Philips Medical Systems, Cleveland, OH, USA) with retrospective electrocardiography (ECG) gating and 3D reconstruction prior to the procedure. Scanning was performed at 120 kVp, with an effective tube current of 600 mAs. The slice collimation was 64 × 0.625 mm, with a gantry rotation time of 0.4 s and a pitch of 0.2. Images were reconstructed at 0.9 mm slice thickness at increments of 0.45 mm. Contrast enhancement with 80 ml of contrast agent (Imeron 400 MCT, Iomeprol 81.65 g/100 ml, Bracco, Konstanz, Germany) was injected at a flow rate of 5 ml/s and followed by a 50-ml saline flush. A blinded observer (JP) analyzed, segmented, and measured each CCTA image visually and quantitatively with regard to the defined parameters and the morphological classification of the LAA using EnSite Precision™ (Abbott Medical GmbH, Eschborn, Germany). Multplan volume-rendered post-processing was used to acquire a 3D perspective. After anatomical segmentation into PV, LA, and LAA, all 2-dimensional (2D) and 3D measurements were conducted.

2.5 Data acquisition, management and quality control

The main 2D parameters included the maximal length, height, and depth of the LAA. The volume of the LAA and LA was computed automatically after anatomical segmentation. Major parameters analyzed three-dimensionally were the LAA length, roof top and bottom lines, distance from the mitral valve annulus to the middle of the LA roof, depth of the LA, and septum orifice distance (see Figure S3). Major subsequent computed parameters were the ellipsoidal area of the LAA ostium, perimeter calculated by Ramanujan’s formula, and trapezoid area of the posterior wall calculated by the roof top line, and roof and bottom lines and the distance between those lines. Based on the criteria established by Wang et al. and Kimura et al., the LAA was classified into one of four types: windsock, chicken-wing, cactus, and cauliflower.16,17 After initial classification, there was a reassessment of all images among a team of four physicians for objective validation. CBA was performed as previously described15,18 (Appendix).

All ablation procedures were performed by experienced interventional electrophysiologists (EH, UD, FS, MW). Following the intervention, all patients were monitored with continuous ECG for at least 24–48 h. TTE was performed to exclude pericardial effusion. In the event of symptoms, additional ECG and Holter studies were continued for up to 7 days. Holter recordings after 1, 3, 6, and at least 12 months were organized to screen for symptomatic or asymptomatic atrial arrhythmias. Follow-up was also ensured in cooperation with referring physicians, and detailed questionnaires (15 questions) were administered for each case via mail and telephone calls. If there was any suspicion of recurrence, the referring physician was contacted to validate the diagnosis. Only recurrences outside of the 90-day blanking period were categorized as failures.

2.6 Statistical analysis

Statistical analysis was performed using Microsoft Excel 2016 (Microsoft Corp., Redmond, WA, USA) and SPSS version 25 (IBM Corp., Armonk, NY, USA). Categorical variables are reported as numbers and percentages. In accordance with the Shapiro–Wilk test, continuous variables are expressed as means with standard deviations (SD) or as medians with quartiles. To assess the relationship between LAA parameters and the recurrence of AF after CBA, univariate Cox regressions and Kaplan–Meier plots with log-rank tests were used. To avoid problems regarding multicollinearity in multivariate models Pearson’s and Spearman’s correlation coefficients were computed to identify inter-variable relationships. Main independent risk factors were determined using a stepwise multivariate Cox regression model with bidirectional elimination including only parameters of highest univariate significance. Parameters highly correlated with these main features were eliminated. Receiver operating characteristic (ROC) analysis with the corresponding area under the curve (AUC) was performed to determine the specific cut-off values. Statistical significance was defined as \( p \leq 0.05 \). All data were analyzed using the SPSS version 25.

3 RESULTS

3.1 Study population and procedural results

From May 2012 to September 2016, 1103 patients underwent PVI for symptomatic paroxysmal or persistent AF. CCTA was performed in 725 (65.7%) patients, and 473 (42.9%) patients had sufficient image quality for LAA measurements. Figure S1 represents a flow diagram of the study. The mean age of patients who underwent PVI was 66.2 ± 9.5 years, of whom, 189 (40%) were females. The majority of patients (58.6%) had symptomatic paroxysmal AF. Table 1 illustrates the baseline characteristics of the study population in terms of recurrence and non-recurrence.

All patients underwent CBA, and all PVs were successfully isolated with the cryoballoon. No additional RF or Cryo-Tip touch-up ablations were performed. The median procedural time was 130 (110; 155) min with an LA time of 90 (75; 110) min. The fluoroscopy time was 22 (17; 27) min, and the median dose area product was 1829 (1044; 3099) cGycm². Of all 473 patients undergoing CBA, 166 (35.1%) experienced AF recurrence during follow-up. The median follow-up time was 19 months.

3.2 LAA morphology and outcome

The distribution of the LAA morphological types is shown in Figure 1. Among the 166 recurrence events, chicken-wing morphology had the highest chance of recurrence at 37.8%, followed by windsock at 36.5%, cauliflower at 32.0%, and cactus at 28.8%. None of these categories was found to have a statistically significant impact on the AF recurrence rate (log-rank; \( p = 0.596 \)). The corresponding Kaplan–Meier plot is illustrated in Figure 2A.
TABLE 1  Baseline characteristics

|                          | All patients | With recurrence | Without recurrence | p-value |
|--------------------------|--------------|-----------------|--------------------|---------|
|                          | Value        | Analyzed        | Value              | Analyzed | Value          | Analyzed |       |
| Age, years               | 66.25 ± 9.47 | 473             | 67.36 ± 9.28       | 166      | 65.65 ± 9.53   | 307      | 0.05  |
| Females (%)              | 189 (40.0)   | 473             | 74 (15.6)          | 166      | 115 (24.3)     | 307      | 0.08  |
| Persistent AF (%)        | 196 (41.4)   | 473             | 82 (17.3)          | 166      | 114 (24.1)     | 307      | 0.006 |
| Mitral regurgitation ≥ II | 18 (3.8)     | 473             | 10 (2.1)           | 166      | 8 (1.7)        | 307      | 0.005 |
| Valve disease ≥ II       | 25 (5.3)     | 473             | 13 (2.7)           | 166      | 12 (2.5)       | 307      | 0.007 |
| LA diametera mm          | 43 [40; 47]  | 440             | 45 [41; 50]        | 159      | 42 [39; 47]    | 281      | 0.002 |
| Ejection fractiona (%)   | 56.88 ± 6.1  | 459             | 56.39 ± 5.64       | 162      | 57.14 ± 6.32   | 297      | 0.72  |
| Hypertension             | 309 (66.2)   | 467             | 112 (24.0)         | 164      | 197 (42.1)     | 303      | 0.51  |
| Hypertensive heart diseasea | 103 (21.8)  | 467             | 43 (9.2)           | 164      | 60 (12.8)      | 303      | 0.10  |
| Cardiomyopathy           | 16 (3.4)     | 466             | 3 (0.6)            | 163      | 13 (2.8)       | 303      | 0.2   |
| Prior myocardial infarction | 8 (1.7)    | 465             | 3 (0.6)            | 162      | 5 (1.1)        | 303      | 0.98  |
| Structural heart disease | 170 (35.9)   | 473             | 69 (14.6)          | 166      | 101 (21.3)     | 307      | 0.042 |
| Overweight (BMI > 25)    | 233 (61.6)   | 378             | 80 (21.2)          | 137      | 153 (40.4)     | 241      | 0.21  |
| Obesity (BMI > 30)       | 67 (17.7)    | 378             | 21 (5.6)           | 137      | 46 (12.2)      | 241      | 0.21  |
| Obesity II/III (BMI > 35) | 20 (5.3)    | 378             | 9 (2.4)            | 137      | 11 (3.0)       | 241      | 0.64  |
| Left common ostiumb      | 101 (21.4)   | 473             | 37 (7.8)           | 166      | 64 (13.5)      | 307      | 0.81  |
| Accessory veinsb         | 83 (17.5)    | 473             | 37 (7.8)           | 166      | 46 (9.7)       | 307      | 0.053 |

Note: n (%), mean ± SD, or median (IQR).
Abbreviations: AF, atrial fibrillation; BMI, body mass index; IQR, interquartile range; LA, left atrium; SD, standard deviation.
aDetermined by transthoracic echocardiography.
bDetermined by contrast enhanced cardiac computer tomography.

FIGURE 1  Classification of LAA morphology. This figure depicts the LAA morphological types as defined by Wang [22] with Kimura’s quantitative qualifiers [23]. According to the measured LAA length and number of lobes, LAA morphology was classified into one of four types: windsock, chicken-wing, cactus, and cauliflower. The prevalent LAA type distribution in the study is provided here. LAA, left atrial appendage.
3.3 | LAA volume and the correlation to LA volume

LAA and LA volumes showed statistically significant correlations. We conducted linear regression to quantify the correlation of the LA volume with the LAA volume, which demonstrated that the LAA volume increased by 0.70 ml per 10 ml increase in LA volume ($p < 0.001$, see Figure S2).

3.4 | LAA morphology

Chicken-wing morphology had the largest LAA volume with 9.9 [7.98; 12.83] ml, followed by windsock morphology with an LAA volume of 9.65 [7.73; 13.08] ml. Cactus and cauliflower morphologies were smaller, with LAA volumes of 5.4 [4.6; 7.5] ml and 5.6 [4.4; 7.6] ml, respectively ($p < 0.001$).
3.5 | Outcome predictors: Univariate analysis

In univariate Cox regression models, four continuous parameters were significant predictors of AF recurrence, with LA volume in ml demonstrating the highest predictive value (hazard ratio [HR] 1.01; 95% confidence interval [CI] 1.006–1.015; \( p < 0.001 \)). The LA volume determined by CCTA seemed to be superior compared to the LA diameter determined by transthoracic echocardiography and showed a higher significance (HR 1.037; 95% CI 1.015–1.060; \( p = 0.001 \)). The second most important parameter was the septum orifice distance (HR 1.053; 95% CI [1.028–1.08]; \( p < 0.001 \)), followed by the trapezoid area of the posterior LA wall (HR 1.01; 95% CI [1–1.001]; \( p < 0.001 \)) and the LAA volume (HR 1.051; 95% CI [1.025–1.078]; \( p < 0.001 \)). All significant results are listed in Table 2 and Table S1.

3.6 | Outcome predictors: Correlation analysis

To avoid problems of multicollinearity in multivariate models, correlation analysis was performed for LA volume and all baseline

| TABLE 2 | Univariate analysis of baseline characteristics and measurement data |
|----------------|----------------------|----------------------|----------------------|
| Univariate analysis | HR 95% CI | p-value |
| Baseline characteristics | | | |
| Female sex | 1.31 | 0.97–1.78 | 0.08 |
| Age, years | 1.02 | 1.000–1.034 | 0.05 |
| Persistent AF | 1.54 | 1.140–2.090 | 0.006 |
| Mitral regurgitation ≥ II | 2.5 | 1.31–4.75 | 0.005 |
| Structural heart disease | 1.38 | 1.01–1.88 | 0.04 |
| LA diameter*, mm | 1.037 | 1.015–1.060 | 0.002 |
| LAA morphology | | | |
| Chicken-wing | 1.13 | 0.781–1.624 | 0.53 |
| Windsock | 1.09 | 0.802–1.476 | 0.59 |
| Cactus | 0.73 | 0.440–1.201 | 0.21 |
| Cauliflower | 0.94 | 0.604–1.459 | 0.78 |
| Significant LAA measurements | | | |
| LAA max width, mm | 1.03 | 1.003–1.049 | 0.03 |
| LAA maximal depth, mm | 1.02 | 1.000–1.036 | 0.05 |
| LAA volume, ml | 1.05 | 1.025–1.078 | <0.0001 |
| LAA Dmax 3D, mm | 1.06 | 1.021–1.107 | 0.003 |
| LAA Dmin 3D, mm | 1.02 | 1.006–1.032 | 0.004 |
| LAA Length, mm | 1.02 | 1.002–1.041 | 0.03 |
| Perimeter LAA ostium, mm | 1.04 | 1.008–1.078 | 0.02 |
| Area LAA ostium, mm² | 1.20 | 1.100–1.300 | 0.001 |
| Significant LA measurements | | | |
| LA volume, 10 ml | 1.100 | 1.060–1.150 | <0.000001 |
| Roof top line, mm | 1.03 | 1.013–1.050 | 0.001 |
| Roof bottom line, mm | 1.03 | 1.012–1.054 | 0.002 |
| Posterior wall box height, mm | 1.03 | 1.003–1.065 | 0.03 |
| Distance MVA-LA roof, mm | 1.04 | 1.014–1.064 | 0.002 |
| Depth of the LA, mm | 1.04 | 1.013–1.067 | 0.003 |
| Septum orifice distance, mm | 1.05 | 1.028–1.080 | <0.0001 |
| Perimeter LIPV ostium, mm | 1.02 | 1.001–1.042 | 0.04 |
| Trapezoid area of the posterior LA wall, cm² | 1.08 | 1.040–1.100 | <0.0001 |

Note: This table illustrates the results of the univariate analysis of all important baseline characteristics and CCTA derived data.

Abbreviations: AF, atrial fibrillation; CCTA, cardiac computed tomography angiography; CI, confidence interval; Dmax, maximal ostial diameter; Dmin, minimal ostial diameter; HR, hazard ratio; LA, left atrium; LAA, left atrial appendage; LIPV, left inferior pulmonary vein; MVA, mitral valve annulus.
*aMeasured by transthoracic echocardiography.
parameters and measurement data according to the Pearson and Spearman tests (see Table S2, Table S3). Among the baseline parameters, mitral regurgitation, AF type, sex, age, structural heart disease, and hypertensive heart disease were significantly correlated to LA volume (the correlation matrix is provided in the Table S2). All CCTA results that related logically to the LA volume, such as the septum orifice distance, depth of the LA, distance of the mitral valve annulus to the LA roof, and trapezoid area of the posterior left atrial wall, showed significant positive correlations, as did the LAA volume and its companion parameters (e.g., perimeter of the LAA ostium or area of the LAA ostium). Details are provided in the Table S3. LA volume was the best CCTA-derived measurement parameter for predicting AF recurrence and was, therefore, included in multivariate regression analysis.

### Table 3: Evaluation of independent risk factors

| Baseline characteristics | Univariate analysis | Multivariate analysis |
|--------------------------|---------------------|----------------------|
|                         | HR                  | 95% CI               | p-value  | HR                  | 95% CI               | p-value  |
| Female sex              | 1.31                | 0.97–1.78            | 0.08     | 1.648               | 1.196–2.271          | 0.002    |
| Age, years              | 1.02                | 1.000–1.034          | 0.05     |                     |                      |          |
| Persistent AF           | 1.54                | 1.140–2.090          | 0.006    |                     |                      |          |
| Mitral regurgitation ≥ II | 2.5                | 1.31–4.75           | 0.005    | 2.270               | 1.189–4.33           | 0.013    |
| Structural heart disease| 1.38                | 1.01–1.88           | 0.04     |                     |                      |          |
| LA diameter mm           | 1.037               | 1.015–1.060          | 0.002    |                     |                      |          |
| CETTA measurements       |                     |                      |          |                     |                      |          |
| LA volume, 10 ml         | 1.100               | 1.060–1.150         | <0.001   | 1.012               | 1.008–1.016          | <0.001   |

Abbreviations: AF, atrial fibrillation; CCTA, cardiac computed tomography angiography; CI, confidence interval; HR, hazard ratio; LA, left atrium.

Univariate analysis of baseline characteristics and measurement data according freedom of AF after cryoballoon ablation provided multiple highly significant parameters. To prevent multicollinearity in the multivariate analysis, CCTA measurements were reduced to LA volume as it represents the most significant univariate parameter and showed highly significant correlation to all other measurement parameters. After stepwise multivariate regression with bidirectional elimination, three parameters could be identified as independent risk factors: female sex, mitral regurgitation ≥ II and LA volume. The statistical significance of the multivariate Cox regression model was p < 0.000001.

#### 3.8 | LA and LAA volume as dynamic predictors for AF recurrence

The cut-off values for the LA and LAA volumes were determined using ROC analysis. LA volumes ≥ 122.7 ml (sensitivity 0.53, specificity 0.69, AUC 0.63) and LAA volumes ≥ 11.25 ml (sensitivity 0.39, and specificity 0.79, AUC 0.59) were associated with AF recurrence. Both cut-off values showed high statistical significance (LA volume [log-rank; p < 0.001] and LAA volume [log-rank; p < 0.001]). The values are depicted in the Kaplan–Meier plots in terms of AF recurrence (Figure 2B,C).

#### 3.9 | Relationship of persistent atrial fibrillation and LAA volume

Persistent AF patients showed both larger LA volumes and LAA volumes as compared to patients with paroxysmal AF (108.2 [92.5; 126.4] ml versus 124.8 [103.3; 148.5], p < 0.001 and 8.3 [6.1; 12.3] ml versus 9.2 [7.2; 12.3] ml, p = 0.005).

#### 3.10 | Gender differences in LA and LAA volumes

The median LA volume was significantly smaller in females as compared to males (108.0 [92.4; 147.1] ml versus 118.1 [102.7; 131.0] ml, p < 0.001), while the median LAA volume of females was similar compared to males (8.4 [5.9; 11.1] ml versus 9.0 [6.8; 12.0] ml, p = 0.09).
4 | DISCUSSION

To the best of our knowledge, this is the largest trial evaluating the impact of LAA anatomy and morphology, determined by pre-procedural CCTA, on the recurrence of atrial arrhythmias after PVI.

LAA morphology was not associated with AF recurrence after cryoballoon PVI. This finding is in contrast to that of Kocyigit et al. who identified a relationship between cauliflower-type LAA morphology and recurrences after CBA. In this sense, therefore, our study must be considered negative. Nevertheless, secondary and exploratory analyses strongly suggest that LAA size has a role in AF recurrence following PVI. First, LA and LAA volumes represent the two major metrics with respect to their ability to predict AF recurrence after PVI. Second, this is the first study to demonstrate a strong correlation between LA and LAA volumes. Third, owing to the large size of the study population, significant cut-off values for LA and LAA volumes as predictors of recurrences were calculated. Fourth, female sex was an independent risk factor for AF recurrence, and gender differences for LA volumes were observed.

LA volume is the unique independent predictor of AF recurrence, whereas LAA volume is dependent on LA size. The risk of recurrence increases by 10% per 10 ml increase of the LA volume. Similarly, with each 1 ml increase of LA volume, the risk of recurrence increases by 5.1%. Revealed cut-off values regarding AF recurrence show that especially patients with LA volumes ≥122.7 ml or LAA volumes ≥11.25 ml are at risk for AF recurrence despite PVI. Interestingly, Teixeira et al. found the LAA volume >8.825 ml to be predictive for recurrence following radiofrequency catheter ablation of AF. Hence, the observation that LAA size plays a role in outcomes of AF ablation seems to be generalisable to ‘PVI only’ strategies in the initial procedure irrespective of the used ablation technique.

Notably, size differences were observed between the LAA morphology types in the present study. The chicken-wing and windsock types were larger than the cactus and cauliflower LAA types. However, even in the pooled analysis of the smaller LAA morphology types (cactus and cauliflower) compared with the larger LAA morphology types (chicken-wing and windsock), there was no association of LAA shape and recurrences. Neither PV size nor PV variations such as a common ostium or additional right PV were associated with recurrence, which confirms the findings of Khouei et al.

LA volume measured by CCTA had a superior predictive value as compared to LA diameter determined by echocardiography. According to the literature, there is no outcome benefit if a CCTA is performed prior to the procedure and the indication for PVI is based on clinical findings. Other important advantages considering echocardiography over pre-procedural CCTA include the absence of radiation, the low costs and the low effort. However, CCTA before the AF ablation procedure may be beneficial for navigation and the identification of PV variants or for the exclusion of CAD as a cause of AF. CCTA might also be used to rule out thrombi prior to ablation as a potential alternative to transesophageal echocardiography. It is unknown if LA volume measured by TTE is equally predictive for recurrence after CBA compared to CCTA LA volume. However, in a multivariate Cox-regression model not including CCTA measurement data, independent clinical predictors of recurrence were mitral insufficiency ≥II, female sex, AF type, and the LA diameter measured by echocardiography. Although this is a weaker model compared to the Cox-regression model using CCTA measurements, it also yields the most important information for the risk assessment of AF recurrence, enables determining the potential benefit of ablation, and should be used in clinical practice.

Female sex has already been described as a clinical predictor of recurrence, but meta-analyses have shown ambiguous evidence for sex-related differences in outcomes with AF ablation. Our results indicated that female sex was an independent risk factor for AF recurrence after CBA. Female patients were older and underrepresented compared with male patients. These results are consistent with those of all AF ablation trials. However, age was not an independent predictor for AF recurrence after CBA, which is in line with the recently published data. Interestingly, LA volume was significantly smaller in females, while the LAA volume in females was similar to that in males. Hypothetically, sex-related differences in the presence of fibrotic atrial myopathy or additional extra-PV trigger sites may explain our observations. Ultimately, the answer to these questions may lead to specific, sex-tailored AF ablation strategies.

The outcome of a ‘PVI only’ strategy in the first ablation procedure is sufficient for the majority of patients, as confirmed by our results. Based on the present study, patients with a large LA volume are more likely to also have large LAA volumes. The LAA is a potential extra-PV trigger. Hypothetically, a larger LAA might yield AF triggers more frequently. During AF ablation, however, the identification of extra-PV triggers is challenging. Strategies for repeat ablation, if all PVs are isolated, must be evaluated further, and studies evaluating the effect of LAA electrical isolation as well as effects on major outcome parameters are underway. However, this concept does expose the patients to additional thromboembolic risk, and extensive LA ablation is associated with a higher rate of acute complications, such as cardiac tamponade. In the interventional treatment of AF, the pre-procedural identification of patients who would benefit from additional ablation beyond PVI would be of significance. Preprocedural CCTA might be a useful imaging modality if LAA dimensions are of interest. For example, this may be important in studies evaluating ablation strategies for patients with recurrences despite successful PVI.

5 | STUDY LIMITATIONS

This was a single-centre observational study with inherent limitations accompanying this type of study design. The data are not fully consecutive because not every patient underwent cardiac CT before the AF ablation procedure, and image quality was not sufficient for LAA assessment in every patient. In addition, LA and LAA volume measurement is influenced by the hydration status of the patient. Although the CCTA was carried out on sober patients, we cannot exclude the possibility of dehydration and different volume loadings among the patients.
Results were based on clinical visits and the evaluation of symptoms, ECG, and Holter monitoring (1–7 days) during routine follow-up. No systematic, continuous monitoring with implantable devices was available. Therefore, asymptomatic recurrences might have been missed. Furthermore, information as to whether the LAA was arrhythmogenic during the CBA procedure was not available; therefore, we were unable to correlate LAA size or morphology with the incidence of LAA triggers.

6 | CONCLUSION

LAA volume was strongly correlated to LA volume and was a dependent predictor of recurrence after cryoballoon PVI. The main independent predictors were LA volume, female sex, and mitral regurgitation ≥ III. LA volume was significantly smaller in females, while the LAA volume in females was similar to that in males. LAA shape was no predictor of arrhythmia-free survival. The role of LAA in AF treatment should be evaluated in further studies. Preprocedural CCTA might be a useful imaging modality if LAA dimensions are of interest, in studies evaluating ablation strategies for patients with recurrences despite successful PVI.

ACKNOWLEDGEMENT

The clinical software EnSite Precision™ (Abbott Medical GmbH, Eschborn, Germany) was provided by Abbott to the local institution for this study exclusively as a research tool.

CONFLICT OF INTEREST

Dr. Straube received honoraria for lectures from Medtronic, Astra Zeneca, Bristol-Myers-Squibb, I.Med.Pro, outside the submitted work; educational support from Pfizer. Dr. Dorwarth reports honoraria for lectures from Medtronic Inc., outside the submitted work. Dr. Hoffmann is head of the department; the department received compensation for participation in clinical research trials outside the submitted work from Abbott, Bayer, Biotronik, Boehringer Ingelheim, Edwards, Elixier, Medtronic, and Stentys. Dr. Hartl participates in the EP fellowship from Boston Scientific, received educational support from Biotronik, Daiichi Sankyo and honoraria for lectures from Bristol Myers Squibb outside the submitted work. Dres. Brück, Crispin, Ebersberger, Helmberger, Pongratz, Tesche, and Wankerl have nothing to declare.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Florian Straube  https://orcid.org/0000-0002-4491-5224
Janis Pongratz  https://orcid.org/0000-0002-4718-8253
Benedikt Brueck  https://orcid.org/0000-0002-4455-4414
Christian Tesche  https://orcid.org/0000-0002-3584-4284

REFERENCES

1. Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/AS/ACE/AHJEC/PCV/EHRA/ merits consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017;14(10):e275-e444.
2. Straube F, Dorwarth U, Schmidt M, Wankerl M, Ebersberger U, Hoffmann E. Comparison of the first and second cryoballoon: high-volume single-center safety and efficacy analysis. Circ Arrhythm Electrophysiol. 2014;7(2):293-299.
3. Gokoglan Y, Mohanty S, Gunes MF, et al. Pulmonary vein Antrum isolation in patients with paroxysmal atrial fibrillation: more than a decade of follow-up. Circ Arrhythm Electrophysiol. 2016;9(5):e003660.
4. Reddy VY, Sediva L, Petru J, et al. Durability of pulmonary vein isolation with Cryoballoon ablation: results from the sustained PV isolation with Arctic front advance (SUPIR) study. J Cardiovasc Electrophysiol. 2015;26(5):493-500.
5. Tilz RR, Heeger CH, Wick A, et al. Ten-year clinical outcome after circumferential pulmonary vein isolation utilizing the Hamburg approach in patients with symptomatic drug-refractory paroxysmal atrial fibrillation. Circ Arrhythm Electrophysiol. 2018;11(2):e005250.
6. Martins RP, Galand V, Cesiari O, et al. The second generation cryoballoon has improved durable isolation of left but not right pulmonary veins: new insights from a multicentre study. Europace. 2018;20(7):1115-1121.
7. De Pooter J, Strisciuglio T, El Haddad M, et al. Pulmonary vein reconnection no longer occurs in the majority of patients after a single pulmonary vein isolation procedure. JACC Clin Electrophysiol. 2019;5(3):295-305.
8. Verma A, Jiang CY, Betts TR, et al. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med. 2015;372(19):1812-1822.
9. Sultan A, Luker J, Andresen D, et al. Predictors of atrial fibrillation recurrence after catheter ablation: data from the German ablation registry. Sci Rep. 2017;7(1):16678.
10. Costa FM, Ferreira AM, Oliveira S, et al. Left atrial volume is more important than the type of atrial fibrillation in predicting the long-term success of catheter ablation. Int J Cardiol. 2015;184:56-61.
11. Takarada K, Stroker E, De Asmundis C, et al. Second-generation cryoballoon ablation for atrial fibrillation- a detailed analysis of the impact of left atrial volume index on clinical outcome. Circ J. 2018;83(1):84-90.
12. Di Biase L, Burkhardt JD, Mohanty P, et al. Left atrial appendage: an underrecognized trigger site of atrial fibrillation. Circulation. 2010;122(2):109-118.
13. Korsholm K, Berti S, Iriart X, et al. Expert recommendations on cardiac computed tomography for planning transcatheter left atrial appendage occlusion. JACC Cardiovasc Interv. 2020;13(3):277-292.
14. Pathan F, Hecht H, Narula J, Marwick TH. Roles of transesophageal echocardiography and cardiac computed tomography for evaluation of left atrial thrombus and associated pathology: a review and critical analysis. JACC Cardiovasc Imaging. 2018;11(4):616-627.
15. Straube F, Hartl S, Dorwarth U, et al. Cryoballoon ablation for persistent atrial fibrillation-large single-center experience. J Cardiol. 2016;68(6):492-497.
16. Wang Y, Di Biase L, Horton RP, Nguyen T, Morhanty P, Natale A. Left atrial appendage studied by computed tomography to help planning for appendage closure device placement. J Cardiovasc Electrophysiol. 2010;21(9):973-982.
17. Kimura T, Takatsuki S, Inagawa K, et al. Anatomical characteristics of the left atrial appendage in cardiogenic stroke with low CHADS2 scores. Heart Rhythm. 2013;10(6):921-925.
18. Straube F, Dorwarth U, Vogt J, et al. Differences of two cryoballoon generations: insights from the prospective multicentre, multinational FREEZE cohort substudy. Europace. 2014;16(10):1434-1442.
19. Kocyigit D, Yalcin MU, Gurses KM, et al. Impact of anatomical features of the left atrial appendage on outcomes after cryoablation for atrial fibrillation. J Cardiovasc Comput Tomogr. 2019;13(2):105-112.
20. Pinto Teixeira P, Martins Oliveira M, Ramos R, et al. Left atrial appendage volume as a new predictor of atrial fibrillation recurrence after catheter ablation. J Interv Card Electrophysiol. 2017;49(2):165-171.

21. Khoueiry Z, Albenque JP, Providencia R, et al. Outcomes after cryoablation vs. radiofrequency in patients with paroxysmal atrial fibrillation: impact of pulmonary veins anatomy. Europace. 2016;18(9):1343-1351.

22. Kistler PM, Rajappan K, Harris S, et al. The impact of image integration on catheter ablation of atrial fibrillation using electroanatomic mapping: a prospective randomized study. Eur Heart J. 2008;29(24):3029-3036.

23. Kuck KH, Brugada J, Furnkranz A, et al. Impact of female sex on clinical outcomes in the FIRE AND ICE trial of catheter ablation for atrial fibrillation. Circ Arrhythm Electrophysiol. 2018;11(5):e006204.

24. Heeger CH, Bellmann B, Fink T, et al. Efficacy and safety of cryoballoon ablation in the elderly: a multicenter study. Int J Cardiol. 2019;278:108-113.

25. Hartl S, Dorwarth U, Pongratz J, et al. Impact of age on the outcome of cryoballoon ablation as the primary approach in the interventional treatment of atrial fibrillation - insights from a large all-comer study. J Cardiovasc Electrophysiol. 2021;32:949-957.

26. Heeger CH, Rillig A, Geisler D, et al. Left atrial appendage isolation in patients not responding to pulmonary vein isolation. Circulation. 2019;139(5):712-715.

27. Chun KRJ, Perrotta L, Bordignon S, et al. Complications in catheter ablation of atrial fibrillation in 3,000 consecutive procedures: balloon versus radiofrequency current ablation. JACC Clin Electrophysiol. 2017;3(2):154-161.

28. Spencer RJ, DeJong P, Fahmy P, et al. Changes in left atrial appendage dimensions following volume loading during percutaneous left atrial appendage closure. JACC Cardiovasc Interv. 2015;8(15):1935-1941.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Straube F, Pongratz J, Hartl S, et al. Cardiac computed tomography angiography-derived analysis of left atrial appendage morphology and left atrial dimensions for the prediction of atrial fibrillation recurrence after pulmonary vein isolation. Clin Cardiol. 2021;44(11):1636-1645. doi:10.1002/clc.23743